These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 27317353

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Biosimilar epoetin zeta: extrapolation of indications and real world utilization experience.
    Dingermann T, Scotte F.
    Expert Opin Biol Ther; 2016 Jul; 16(7):967-74. PubMed ID: 27227424
    [Abstract] [Full Text] [Related]

  • 3. Biosimilars: the science of extrapolation.
    Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK.
    Blood; 2014 Nov 20; 124(22):3191-6. PubMed ID: 25298038
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Differentiating biosimilarity and comparability in biotherapeutics.
    Azevedo V, Hassett B, Fonseca JE, Atsumi T, Coindreau J, Jacobs I, Mahgoub E, O'Brien J, Singh E, Vicik S, Fitzpatrick B.
    Clin Rheumatol; 2016 Dec 20; 35(12):2877-2886. PubMed ID: 27734233
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Opportunities and challenges of extrapolation for biosimilars].
    Weise M, Wolff-Holz E.
    Z Gastroenterol; 2016 Nov 20; 54(11):1211-1216. PubMed ID: 27711947
    [Abstract] [Full Text] [Related]

  • 8. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J.
    Regul Toxicol Pharmacol; 2016 Apr 20; 76():199-208. PubMed ID: 26732800
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS, Ruiz S, Schneider CK.
    BioDrugs; 2013 Jun 20; 27(3):203-11. PubMed ID: 23553340
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The approval process for biosimilar erythropoiesis-stimulating agents.
    Wish JB.
    Clin J Am Soc Nephrol; 2014 Sep 05; 9(9):1645-51. PubMed ID: 24970875
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
    Ogura M, Coiffier B, Kwon HC, Yoon SW.
    Future Oncol; 2017 May 05; 13(15s):45-53. PubMed ID: 28482699
    [Abstract] [Full Text] [Related]

  • 19. Biosimilar biologic drugs: a new frontier in medical care.
    Geynisman DM, De Velasco G, Sewell KL, Jacobs I.
    Postgrad Med; 2017 May 05; 129(4):460-470. PubMed ID: 28343424
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.